BRIEF published on 02/25/2025 at 19:08, 1 year 6 months ago Adocia: Financial report for the fourth quarter of 2024 Diabetes Treasury Partnership ADOCIA BioChaperone®
BRIEF published on 02/25/2025 at 19:08, 1 year 6 months ago Adocia : Bilan financier du quatrième trimestre 2024 Partenariat Trésorerie Diabète ADOCIA BioChaperone®
PRESS RELEASE published on 02/25/2025 at 19:03, 1 year 6 months ago Inside Information / News release on accounts, results Adocia reports Q4 2024 financial results, €7.5M cash position, partnership updates with Sanofi, and business priorities. Strong revenue growth detailed in press release Financial Results Revenue Growth ADOCIA Partnership Updates Business Priorities
PRESS RELEASE published on 02/25/2025 at 19:03, 1 year 6 months ago Informations privilégiées / Communiqué sur comptes, résultats Adocia publie ses résultats financiers du quatrième trimestre 2024, fait le point sur ses activités et annonce des avancées prometteuses en recherche pour le traitement du diabète et de l'obésité Résultats Financiers Innovations Obésité Diabète ADOCIA
BRIEF published on 02/11/2025 at 14:03, 1 year 7 months ago Threshold crossing at ADOCIA by the CDC Actions Threshold Crossing Bpifrance ADOCIA Deposit Fund
BRIEF published on 02/11/2025 at 14:03, 1 year 7 months ago Franchissement de seuil chez ADOCIA par la CDC Franchissement De Seuil Actions Bpifrance Caisse Des Dépôts ADOCIA
PRESS RELEASE published on 02/11/2025 at 13:58, 1 year 7 months ago Franchissement de seuil Déclaration de franchissement de seuil par la Caisse des dépôts et consignations pour le compte de Bpifrance Investissement concernant ADOCIA sur Euronext Paris Euronext Paris Franchissement De Seuil Caisse Des Dépôts ADOCIA Bpifrance Investissement
BRIEF published on 12/23/2024 at 18:40, 1 year 8 months ago Adocia announces its participation in key conferences in 2025 Investors Biopharmaceutical ADOCIA Conférences 2025 Diabetes And Obesity
BRIEF published on 12/23/2024 at 18:40, 1 year 8 months ago Adocia annonce sa participation à des conférences clés en 2025 Biopharmaceutique Investisseurs ADOCIA Conférences 2025 Diabète Et Obésité
PRESS RELEASE published on 12/23/2024 at 18:35, 1 year 8 months ago Informations privilégiées / Autres communiqués Adocia annonce sa participation à des conférences investisseurs en 2025. Découvrez les événements à venir et les plateformes abordées Biopharmaceutique Conférences Investisseurs Obésité Diabète ADOCIA
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
